(Q37993454)

26 August 2017

title

Eliminating the HIV reservoir (English)

1 reference

26 August 2017

Alain Lafeuillade

1

1 reference

26 August 2017

publication date

1 June 2012

1 reference

26 August 2017

published in

Current HIV/AIDS reports

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

121-131

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-012-0115-y

26 August 2017

exact match

0 references

cites work

Thirty years of HIV and AIDS: future challenges and opportunities

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

The challenge of finding a cure for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

21 January 2018

Macrophages and HIV-1.

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Can HIV infection be eradicated through use of potent antiviral agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Achieving a quantitative understanding of antiretroviral drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Responsiveness of HIV-specific CD4 T cells to PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Emerging concepts in the immunopathogenesis of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Elite controllers as a model of functional cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Potential strategies for an HIV infection cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Introduction: challenges to finding a cure for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Quantitative image analysis of HIV-1 infection in lymphoid tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Eradication of HIV from the brain: reasons for pause

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Therapy for persistent HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Pharmaceutical approaches to eradication of persistent HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Curing HIV: Pharmacologic approaches to target HIV-1 latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Mechanisms of HIV latency: an emerging picture of complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Eradication therapies for HIV Infection: time to begin again

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Histone deacetylase inhibitors and HIV latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Activation of latent HIV using drug-loaded nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Combinatorial latency reactivation for HIV-1 subtypes and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Can HIV be cured with stem cell therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Gene therapy strategies: can we eradicate HIV?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Specific eradication of HIV-1 from infected cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-012-0115-Y

Profaning the ultimate sanctuary: HIV latency in hematopoietic stem cells

21 January 2018

1 reference

12 December 2020

Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2

1 reference

12 December 2020

HIV reservoirs: the new frontier.

1 reference

12 December 2020

New tools to track HIV

1 reference

12 December 2020

The enemy within: dormant retroviruses awaken

1 reference

12 December 2020

HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts

1 reference

12 December 2020

The emerging race to cure HIV infections

1 reference

12 December 2020

Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection

1 reference

12 December 2020

HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors

1 reference

12 December 2020

A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ.

1 reference

12 December 2020

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

12 December 2020

10.1007/S11904-012-0115-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference